Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study

Lancet

Volumn 353, Issue 9170, 1999, Pages 2093-2099

  Carr, Andrew ^a   Samaras, Katherine ^c   Thorisdottir, Anna ^a   Kaufmann, Gilbert R ^a   Chisholm, Donald J ^c   Cooper, David A ^b  

^a ST VINCENT S HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

C PEPTIDE; GLUCOSE; INDINAVIR; NELFINAVIR; PROTEINASE INHIBITOR; RITONAVIR; SAQUINAVIR; TRIACYLGLYCEROL;

ADULT; ARTICLE; BODY COMPOSITION; COHORT ANALYSIS; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; DISEASE SEVERITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LIPODYSTROPHY; MAJOR CLINICAL STUDY; MALE; ORAL GLUCOSE TOLERANCE TEST; PHYSICAL EXAMINATION; PRIORITY JOURNAL; QUESTIONNAIRE;

EID: 0033583977     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)08468-2     Document Type: Article

References (33)

1. Carr A., Samaras K., Burton S.et al. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors. AIDS. 12:1998;F51-58.
2. Viraben R., Aquilina C. Indinavir-associated lipodystrophy. AIDS. 12:1998;F37-39.
3. Miller K.D., Jones E., Yanovski J.A., Shankar R., Feuerstein I., Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet. 351:1998;871-875.
4. Herry I., Bernard L., de Truchis P., Perronne C. Hypertrophy of the breasts in a patient reated with indinavir. Clin Infect Dis. 25:1997;937-938.
5. Lo J.C., Mulligan K., Tai V.W., Algren H., Schambelan M. "Buffalo hump" in men with HIV-1 infection. Lancet. 351:1998;867-870.
6. Roth V.R., Kravcik S., Angel J.B. Development of cervical fat pads following therapy with human immunodeficiency virus type 1 protease inhibitors. Clin Infect Dis. 27:1998;65-67.
7. Miller K.K., Daly P.A., Sentochnik D.et al. Pseudo-Cushing's syndrome in human immunodeficiency virus-infected patients. Clin Infect Dis. 27:1998;68-72.
8. Striker R., Conlin D., Marx M., Wiviott L. Localized adipose tissue hypertrophy in patients receiving human immunodeficiency virus protease inhibitors. Clin Infect Dis. 27:1998;218-220.
9. Rosenburg, H.E., Mulder, J., Septowitz, K.A., Giordano, M.F."Protease-paunch" in HIV+ persons receiving protease inhibitor therapy: incidence, risks and endocrinologic evaluation. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February, 1998 (abstr 408).
10. Deeks S.G., Smith M., Holodniy M., Kahn J.O. HIV-1 protease inhibitors: a review for clinicians. JAMA. 277:1997;145-153.
11. Lumpkin MM. Reports of diabetes and hyperglycemia in patients receiving protease inhibitors for the treatment of human immunodeficiency virus infection. Bethesda, MD: FDA Public Health Advisory, June 11, 1997.
12. Dubé M.P., Johnson D.L., Currier J.S., Leedom J.M. Protease inhibitor-associated hyperglycaemia. Lancet. 350:1997;713-714.
13. Keruly JE, Chaisson RE, Moore RD. Diabetes and hyperglycemia in patients receiving protease inhibitors. 5th Conference on Retroviruses and Opportunistic Infections, Chicago, February, 1998 (abstr 415).
14. Carr A., Samaras K., Chisholm D.J., Cooper D.A. Pathogenesis of HIV-1-protease inhibitor-associated peripheral lipodystrophy, hyperlipidaemia, and insulin resistance. Lancet. 351:1998;1881-1883.
15. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 21:1998;S5-19.
16. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 89:1993;1333-1445.
17. Fuller J.H., Shipley M.J., Rose G., Jarrett R.J., Keen H. Coronary-heart-disease risk and impaired glucose tolerance: the Whitehall study. Lancet. i:1980;1373-1376.
18. Jeppesen J., Hein H.O., Suadicani P., Gyntelberg F. Triglyceride concentration and ischaemic heart disease: an eight-year follow-up in the Copenhagen Male Study. Circulation. 97:1998;1029-1036.
19. Hokanson K.E., Austin M.A. Plasma trigyceride is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk. 3:1996;213-219.
20. Gaziano J.M., Hennekens C.H., O'Donnell C.J., Breslow J.L., Buring J.E. Fasting triglycerides, high-density lipoprotein and risk of myocardial infarction. Circulation. 96:1997;2520-2525.
21. Lamarche B., Deprés J.P., Moorjani S., Cantin B., Dagenais G.R., Lupien P.J. Triglycerides and HDL-cholesterol as risk factors for ischaemic heart disease: results from the Quebec cardiovascular study. Atherosclerosis. 119:1996;235-245.
22. Stampfer M.J., Krauss R.M., Ma J.et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA. 276:1996;882-888.
23. Burchfield C.M., Laws A., Benfante R.et al. Combined effects of HDL cholesterol, triglyceride and total cholesterol concentrations on 18 year risk of atherosclerotic disease. Circulation. 92:1995;1430-1436.
24. Matthews D.R., Hosker J.P., Rudenski A.S., Naylor B.A., Treacher D.F., Turner R.C. Homeostasis model assessment: insulin resistance and B-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia. 28:1985;412-419.
25. O'Sullivan A., Kelly J.J., Hoffman D.M., Freund J., Ho K.K.Y. Body composition and energy expenditure in acromegaly. J Clin Endocrinol Metab. 78:1994;381-386.
26. Mazess R.B., Barden H.S., Bisek J.P., Hanson J. Dual-energy x-ray absorptiometry for total-body and regional bone-mineral and soft-tissue composition. Am J Clin Nutr. 51:1990;1106-1112.
27. Haarbo J., Gotfredson A., Hassager C., Christiansen C. Validation of body composition by dual-energy x-ray absorptiometry (DEXA). Clin Physiol. 11:1991;331-341.
28. Welborn T.A., Reid C.M., Marriott G. Australian Diabetes Screening Study: impaired glucose tolerance and non-insulin-dependent diabetes mellitus. Metab Clin Exp. 46(1):1997;35-39.
29. Coyle P., Carr A., Depczynski B.B., Chisholm D.J. Diabetes mellitus associated with pentamidine use in HIV-infected patients. Med J Aust. 165:1996;587-588.
30. Chidiac C., Alfandari S., Caron J., Mouton Y. Diabetes mellitus following treatment of AIDS with didanosine. AIDS. 9:1995;215-216.
31. Unger R.H. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM. Diabetes. 144:1995;863-870.
32. Danner S.A., Carr A., Leonard J.et al. Safety, pharmacokinetics and preliminary efficacy of ritonavir, an inhibitor of HIV-1 protease. N Engl J Med. 333:1995;1528-1533.
33. Markowitz M., Saag M., Powderly W.G.et al. A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. N Engl J Med. 33:1995;1534-1539.